202 related articles for article (PubMed ID: 38398096)
1. Infrequent Presentations of Chronic
Castaño-Díez S; Guijarro F; López-Guerra M; Pérez-Valencia AI; Gómez-Núñez M; Colomer D; Díaz-Beyá M; Esteve J; Rozman M
Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398096
[TBL] [Abstract][Full Text] [Related]
2.
Forghieri F; Nasillo V; Paolini A; Bettelli F; Pioli V; Giusti D; Gilioli A; Colasante C; Acquaviva G; Riva G; Barozzi P; Maffei R; Potenza L; Marasca R; Fozza C; Tagliafico E; Trenti T; Comoli P; Longo G; Luppi M
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255988
[TBL] [Abstract][Full Text] [Related]
3. Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms.
Schnittger S; Bacher U; Haferlach C; Alpermann T; Dicker F; Sundermann J; Kern W; Haferlach T
Leukemia; 2011 Apr; 25(4):615-21. PubMed ID: 21233837
[TBL] [Abstract][Full Text] [Related]
4. Pattern associated leukemia immunophenotypes and measurable disease detection in acute myeloid leukemia or myelodysplastic syndrome with mutated NPM1.
Zhou Y; Moon A; Hoyle E; Fromm JR; Chen X; Soma L; Salipante SJ; Wood BL; Wu D
Cytometry B Clin Cytom; 2019 Jan; 96(1):67-72. PubMed ID: 30417521
[TBL] [Abstract][Full Text] [Related]
5. Chronic myelomonocytic leukemia associated with myeloid sarcomas and
Matanes F; AbdelAzeem BMA; Shah G; Reddy V; Saad A; Papadantonakis N
Ther Adv Hematol; 2019; 10():2040620719854596. PubMed ID: 31217941
[TBL] [Abstract][Full Text] [Related]
6. Chronic myelomonocytic leukemia with nucleophosmin (NPM1) mutation.
Peng J; Zuo Z; Fu B; Oki Y; Tang G; Goswami M; Priyanka P; Muzzafar T; Medeiros LJ; Luthra R; Wang SA
Eur J Haematol; 2016 Jan; 96(1):65-71. PubMed ID: 25809997
[TBL] [Abstract][Full Text] [Related]
7. The Role of Nucleophosmin 1 (
Kelemen K
Life (Basel); 2022 Jan; 12(1):. PubMed ID: 35054502
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic and genetic characterization of nonacute
Patel SS; Ho C; Ptashkin RN; Sadigh S; Bagg A; Geyer JT; Xu ML; Prebet T; Mason EF; Seegmiller AC; Morgan EA; Steensma DP; Winer ES; Wong WJ; Hasserjian RP; Weinberg OK
Blood Adv; 2019 May; 3(9):1540-1545. PubMed ID: 31085507
[No Abstract] [Full Text] [Related]
9. How I diagnose and treat NPM1-mutated AML.
Falini B; Brunetti L; Martelli MP
Blood; 2021 Feb; 137(5):589-599. PubMed ID: 33171486
[TBL] [Abstract][Full Text] [Related]
10. [Molecular features of 109 patients with chronic myelomonocytic leukemia in a single center].
Qu SQ; Pan LJ; Qin TJ; Xu ZF; Li B; Wang HJ; Sun Q; Jia YJ; Li CW; Cai WY; Gao QY; Jiao M; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2023 May; 44(5):373-379. PubMed ID: 37550186
[No Abstract] [Full Text] [Related]
11. Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia.
Helbig G; Chromik K; Woźniczka K; Kopińska AJ; Boral K; Dworaczek M; Koclęga A; Armatys A; Panz-Klapuch M; Markiewicz M
Pathol Oncol Res; 2019 Jul; 25(3):1175-1180. PubMed ID: 30613922
[TBL] [Abstract][Full Text] [Related]
12. Progression in Myeloid Neoplasms: Beyond the Myeloblast.
Faria C; Tzankov A
Pathobiology; 2024; 91(1):55-75. PubMed ID: 37232015
[TBL] [Abstract][Full Text] [Related]
13. Blast phenotype and comutations in acute myeloid leukemia with mutated NPM1 influence disease biology and outcome.
Mason EF; Hasserjian RP; Aggarwal N; Seegmiller AC; Pozdnyakova O
Blood Adv; 2019 Nov; 3(21):3322-3332. PubMed ID: 31698462
[TBL] [Abstract][Full Text] [Related]
14. Coexisting and cooperating mutations in NPM1-mutated acute myeloid leukemia.
Patel JL; Schumacher JA; Frizzell K; Sorrells S; Shen W; Clayton A; Jattani R; Kelley TW
Leuk Res; 2017 May; 56():7-12. PubMed ID: 28152414
[TBL] [Abstract][Full Text] [Related]
15. Single-center, observational study of AML/MDS-EB with IDH1/2 mutations: genetic profile, immunophenotypes, mutational kinetics and outcomes.
Papadopoulou V; Schoumans J; Basset V; Solly F; Pasquier J; Blum S; Spertini O
Hematology; 2023 Dec; 28(1):2180704. PubMed ID: 36815747
[TBL] [Abstract][Full Text] [Related]
16. CD123 Is Consistently Expressed on
Perriello VM; Gionfriddo I; Rossi R; Milano F; Mezzasoma F; Marra A; Spinelli O; Rambaldi A; Annibali O; Avvisati G; Di Raimondo F; Ascani S; Falini B; Martelli MP; Brunetti L
Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33525388
[No Abstract] [Full Text] [Related]
17. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
[TBL] [Abstract][Full Text] [Related]
18. Whole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): A unique molecular-cytogenetic subgroup.
Hong M; Hao S; Patel KP; Kantarjian HM; Garcia-Manero G; Yin CC; Medeiros LJ; Lin P; Lu X
Cancer Genet; 2016 May; 209(5):205-14. PubMed ID: 27134073
[TBL] [Abstract][Full Text] [Related]
19. NPM1-mutated AML-MRC diagnosed on the basis of history of MDS or MDS/MPN frequently harbours secondary-type mutations and confers inferior outcome compared to AML with mutated NPM1.
Zhao D; Zarif M; Eladl E; Capo-Chichi JM; Smith AC; Atenafu EG; Tierens A; Minden MD; Schuh A; Chang H
Leuk Res; 2022 Jul; 118():106869. PubMed ID: 35636054
[TBL] [Abstract][Full Text] [Related]
20. Classification of acute myeloid leukemia by the revised fourth edition World Health Organization criteria: a retrospective single-institution study with appraisal of the new entities of acute myeloid leukemia with gene mutations in NPM1 and biallelic CEBPA.
Kansal R
Hum Pathol; 2019 Aug; 90():80-96. PubMed ID: 31077683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
